4//SEC Filing
Baldry Mark 4
Accession 0001628280-25-005698
CIK 0001501697other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:08 PM ET
Size
8.4 KB
Accession
0001628280-25-005698
Insider Transaction Report
Form 4
Baldry Mark
Chief Commercial Officer
Transactions
- Purchase
Common Stock
2024-05-17$0.68/sh+21,646$14,654→ 115,769 total - Purchase
Common Stock
2024-11-15$0.34/sh+13,404$4,598→ 129,173 total - Award
Common Stock
2025-02-12+600,000→ 729,173 total
Footnotes (2)
- [F1]The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported.
- [F2]Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.
Documents
Issuer
X4 Pharmaceuticals, Inc
CIK 0001501697
Entity typeother
Related Parties
1- filerCIK 0001644137
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 4:08 PM ET
- Size
- 8.4 KB